Inventaire - your friends and communities are your best library

Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment

Author

Beatriz Grinsztejn

Valdiléa G Veloso

Mariza Gonçalves Morgado

Jose Henrique Pilotto

Vera Bongertz

Published in: Memórias do Instituto Oswaldo Cruz

Date of publication: November 1, 2007

Language: English

Main subject: anti-retroviral agent

Bibliographic databases:

Cites articles 34

Date

Title

Authors

July 1, 1998

Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy,Evolution of Cytotoxic T Lymphocyte Responses to Human Immunodeficiency Virus Type 1 in Patients with Symptomatic Primary Infection Receiving Antiretroviral Triple Therapy

,
July 1, 1998

HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy
November 1, 1999

Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
August 1, 2000

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection
February 1, 2000

HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. Brazilian Network for HIV Isolation and Characterization

,
July 1, 2000

Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication

, ,
March 1, 2001

Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity

, ,
February 1, 2001

Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?
December 14, 2001

Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy,Reconstitution of Spontaneous Neutralizing Antibody Response against Autologous Human Immunodeficiency Virus during Highly Active Antiretroviral Therapy
October 1, 2001

Systematic determination of the packaging limit of lentiviral vectors
November 1, 2001

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection
December 1, 2001

Characterization of the HIV-1 Specific Humoral Immune Response During Highly Active Antiretroviral Therapy (HAART)
March 1, 2002

Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity
November 1, 2002

High frequency of recombinant genomes in HIV type 1 samples from Brazilian southeastern and southern regions

, ,
February 14, 2002

Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy
July 1, 2003

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

, , , , , , ,
June 1, 2003

Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy
April 1, 2004

Isotype profiles of anti-gp160 antibodies from HIV-infected patients in plasma and culture supernatants
April 1, 2004

CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome
April 1, 2004

Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia

,
June 1, 2004

Primary HIV-1 drug resistance in Brazil

,
February 1, 2005

Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals
September 30, 2005

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy

,
June 14, 2005

Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response

, , , , ,
June 1, 2006

Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.
May 1, 2006

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy

, , , ,
August 1, 2006

Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine
February 16, 2006

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load

, , ,
April 1, 2006

Molecular epidemiology of HIV-1 infection in a small Brazilian county: usefulness of envelope and polymerase sequences to epidemiologic studies

,
July 1, 2006

The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response.

, , , ,
September 2006

Low CD4+T Cell Nadir Is an Independent Predictor of Lower HIV‐Specific Immune Responses in Chronically HIV‐1–Infected Subjects Receiving Highly Active Antiretroviral Therapy

, ,
June 1, 2006

Millions of life-years saved with potent antiretroviral drugs in the United States: a celebration, with challenges

Article -

Welcome to inventaire

The library of your friends and communities

Learn more